Coston McIsaac & Partners’s Avanos Medical AVNS Stock Holding History

Coston McIsaac & Partners’s Portfolio AVNS Stock Details AVNS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$0	Hold	8	–	–	﹤0.01%	843
2026 Q1	$0	Hold	8	–	–	﹤0.01%	834
2025 Q4	$0	Sell	8 -5	-38%	-$57	﹤0.01%	827
2025 Q3	$0	Hold	13	–	–	﹤0.01%	789
2025 Q2	$0	Buy	+13	New	+$163	﹤0.01%	758
2025 Q1	–	Sell	-13	Closed	–	–	754
2024 Q4	$0	Hold	13	–	–	﹤0.01%	751
2024 Q3	$0	Hold	13	–	–	﹤0.01%	754
2024 Q2	$0	Hold	13	–	–	﹤0.01%	733
2024 Q1	$0	Hold	13	–	–	﹤0.01%	717
2023 Q4	$0	Hold	13	–	–	﹤0.01%	718
2023 Q3	$0	Hold	13	–	–	﹤0.01%	719
2023 Q2	$0	Hold	13	–	–	﹤0.01%	766
2023 Q1	$0	Buy	13 +8	+160%	+$232	﹤0.01%	796
2022 Q4	$0	Hold	5	–	–	﹤0.01%	766
2022 Q3	$0	Hold	5	–	–	﹤0.01%	685
2022 Q2	$0	Buy	+5	New	+$144	﹤0.01%	474

Other funds holding AVNS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

NAM

Nexpoint Asset Management Dallas, Texas $1.5B AUM 83.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

TAL

TIG Advisors LLC New York $2.26B AUM 81.38% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

FTCM

First Trust Capital Management Chicago, Illinois $1.72B AUM 70.66% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Coston McIsaac & Partners's AVNS Position: Q2 2026 in Review

Coston McIsaac & Partners held its Avanos Medical (AVNS) position steady in Q2 2026 at 8 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #843.

Coston McIsaac & Partners first reported a position in AVNS in Q2 2022 and has held it in 16 quarters since. 286 funds tracked by Wall St. Rank hold AVNS as of Q2 2026.

Coston McIsaac & Partners held 8 shares of Avanos Medical worth $0 as of Q2 2026.
Coston McIsaac & Partners left its Avanos Medical share count unchanged in Q2 2026.
Avanos Medical made up ﹤0.01% of Coston McIsaac & Partners's portfolio in Q2 2026, its #843 holding.
Coston McIsaac & Partners first reported a position in Avanos Medical in Q2 2022 and has held it in 16 quarters since.
286 funds tracked by Wall St. Rank held Avanos Medical as of Q2 2026.

Based on Coston McIsaac & Partners's 13F filing for Q2 2026, filed 12 Aug 2026.